<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Vroegindeweij LHP</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Aceruloplasminemia is a rare genetic iron overload disorder, characterized by progressive neurological manifestations. The effects of iron chelation on neurological outcomes have only been described in case studies, and are inconsistent. Aggregated case reports were analyzed to help delineate the disease-modifying potential of treatment.&lt;h4>Methods&lt;/h4>Data on clinical manifestations, treatment and neurological outcomes of treatment were collected from three neurologically symptomatic Dutch patients, who received deferiprone with phlebotomy as a new therapeutic approach, and combined with other published cases. Neurological outcomes of treatment were compared between patients starting treatment when neurologically symptomatic and patients without neurological manifestati</pubmed_abstract><journal>Orphanet journal of rare diseases</journal><pagination>105</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7183696</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.</pubmed_title><pmcid>PMC7183696</pmcid><pubmed_authors>Wilson JHP</pubmed_authors><pubmed_authors>Boon AJW</pubmed_authors><pubmed_authors>Vroegindeweij LHP</pubmed_authors><pubmed_authors>Langendonk JG</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.</name><description>&lt;h4>Background&lt;/h4>Aceruloplasminemia is a rare genetic iron overload disorder, characterized by progressive neurological manifestations. The effects of iron chelation on neurological outcomes have only been described in case studies, and are inconsistent. Aggregated case reports were analyzed to help delineate the disease-modifying potential of treatment.&lt;h4>Methods&lt;/h4>Data on clinical manifestations, treatment and neurological outcomes of treatment were collected from three neurologically symptomatic Dutch patients, who received deferiprone with phlebotomy as a new therapeutic approach, and combined with other published cases. Neurological outcomes of treatment were compared between patients starting treatment when neurologically symptomatic and patients without neurological manifestati</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Apr</publication><modification>2026-05-01T20:01:33.65Z</modification><creation>2020-05-22T18:45:30Z</creation></dates><accession>S-EPMC7183696</accession><cross_references><pubmed>32334607</pubmed><doi>10.1186/s13023-020-01385-w</doi></cross_references></HashMap>